Aardvark Therapeutics Inc(AARD) - 2025 Q1 - Quarterly Results

Financial Performance - Aardvark Therapeutics raised $97.9 million in gross proceeds from its IPO, with net proceeds of approximately$87.5 million[3]. - The net loss for Q1 2025 was $9.3 million, compared to a net loss of$2.2 million in Q1 2024[7]. - Total operating expenses for Q1 2025 were $10.5 million, significantly higher than$2.2 million in Q1 2024[11]. - The weighted-average shares used in the net loss per share calculation for Q1 2025 were approximately 13.2 million[11]. Cash and Investments - As of March 31, 2025, Aardvark had cash, cash equivalents, and short-term investments totaling $151.3 million, sufficient to fund operations into 2027[6]. - Total assets as of March 31, 2025, were$157.0 million, up from $77.5 million at the end of 2024[13]. Research and Development - Research and development expenses increased to$7.8 million for Q1 2025, up from $1.2 million in Q1 2024, reflecting a$6.6 million increase[6]. - Aardvark's lead candidate, ARD-101, is in Phase 3 clinical development for treating hyperphagia associated with Prader-Willi Syndrome, with data readout expected in early 2026[5]. - Aardvark is also developing ARD-201, a fixed-dose combination aimed at addressing limitations of current GLP-1 therapies for obesity[8]. General and Administrative Expenses - General and administrative expenses rose to $2.7 million in Q1 2025, compared to$0.9 million in Q1 2024, marking a $1.9 million increase[6].